Trawling for Genes That Predict Response to Breast Cancer Adjuvant Therapy
- 15 June 2004
- journal article
- editorial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 22 (12) , 2267-2269
- https://doi.org/10.1200/jco.2004.03.950
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Gene Expression Profiles Predict Complete Pathologic Response to Neoadjuvant Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide Chemotherapy in Breast CancerJournal of Clinical Oncology, 2004
- Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancerThe Lancet, 2003
- Repeated observation of breast tumor subtypes in independent gene expression data setsProceedings of the National Academy of Sciences, 2003
- “Hands-on” WorkshopsEuropean Radiology, 2003
- Design of studies using DNA microarraysGenetic Epidemiology, 2002
- Neoadjuvant Chemotherapy in Breast Cancer: Significantly Enhanced Response With DocetaxelJournal of Clinical Oncology, 2002
- Comparison of Discrimination Methods for the Classification of Tumors Using Gene Expression DataJournal of the American Statistical Association, 2002
- Gene expression profiling predicts clinical outcome of breast cancerNature, 2002
- Letrozole Is More Effective Neoadjuvant Endocrine Therapy Than Tamoxifen for ErbB-1– and/or ErbB-2–Positive, Estrogen Receptor–Positive Primary Breast Cancer: Evidence From a Phase III Randomized TrialJournal of Clinical Oncology, 2001
- Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.Journal of Clinical Oncology, 1998